science
Eli Lilly Acquires Kelonia Therapeutics for $3 Billion as Biotech Sector Sees New Developments
Eli Lilly completed a $3 billion acquisition of Kelonia Therapeutics, according to reports. A venture capital partner shared the original investment memo and slide deck for Kelonia. Other biotech news includes BioAge's inflammation trial results, a Pfizer executive departure, and the launch of Tortugas Neuroscience.
Apr 21, 9:57 AM·1m read1 source
ST
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly acquired Kelonia Therapeutics for $3 billion, @statnews reported. A partner at the venture capital firm that incubated Kelonia Therapeutics shared the original investment memo and slide deck used to start Kelonia, following the acquisition news. BioAge is developing drugs targeting inflammation to treat chronic conditions, the company stated.
BioAge's experimental pill aimed at reducing heart risks reduced inflammation in an early trial, according to BioAge. A former banker brought on to revitalize Pfizer’s strategy departed his post on April 20, 2026, @statnews reported. Tortugas Neuroscience launched on April 21, 2026, to develop drugs for brain disorders and other conditions.
In an early trial, CAR-T results raised hope of preventing multiple myeloma in high-risk patients, @statnews reported. The STAT Plus Newsletter The Readout was published on April 21, 2026, via STAT. Elaine Chen is the National Biotech Reporter for STAT.
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast The Readout Loud. 70. At AACR on April 20, 2026, there was a provocative use of CAR-T, Merck’s new development, and discussion of cancer’s geography problem, @statnews reported.
STAT Plus reported on April 20, 2026, about early trial CAR-T results for multiple myeloma prevention. The article was written by Elaine Chen on April 21, 2026.
